Common contact surface used in production, packaging, delivery, and evaluation of biopharmaceutical product
A system with SiOxCy or SiNxCy coated containers and connectors addresses contamination and instability issues in biopharmaceutical products by ensuring compatibility and compliance, improving yield and quality while accelerating regulatory approval.
Patent Information
- Application Number
- JP2024137822
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-01-25
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-15
AI Technical Summary
Biopharmaceutical products are susceptible to contamination, instability, and reduced quality due to interactions with various contact surfaces during manufacturing, packaging, and distribution, particularly in single-use plastic containers that can leach chemicals, affecting yield, quality, and regulatory compliance.
Implementing a system with containers and connectors featuring a common surface coating composed of SiOxCy or SiNxCy coatings, including a bonding, barrier, and optionally a pH protective layer, to minimize interactions and ensure compatibility with biopharmaceutical products.
This approach reduces potential problems with yield, quality, and potency of biopharmaceutical products, streamlines regulatory approval, and enhances the efficiency of manufacturing, packaging, and distribution processes.
Smart Images

Figure 2024161031000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 797,028, filed January 25, 2019, and incorporates by reference thereto in its entirety.
[0002] The present disclosure relates to a system characterized by two or more containers and / or connectors having a common surface that contacts a biopharmaceutical product during manufacturing, packaging and distribution. The present disclosure also relates to methods for determining and improving compatibility with contact surfaces of biological materials, biopharmaceutical compositions, and their precursors and intermediates (collectively, biopharmaceutical products), and for providing a system characterized by two or more containers and / or connectors having a customized common surface that contacts a biopharmaceutical product or its precursors and intermediates during manufacturing, packaging and distribution of the biopharmaceutical product.
[0003] The present disclosure relates generally to a system of containers or other devices, two or more of which are characterized by common surfaces that contact biopharmaceutical products during manufacture, packaging, and distribution. These common surfaces are present in substantially all areas of the walls of the containers or other devices where the walls contact the biopharmaceutical products and / or compositions that comprise them, precursors or intermediates of the biopharmaceutical products, and / or biological materials used to manufacture the biopharmaceutical products or for use as therapeutics. Additionally, the present disclosure relates to the development of customized common surfaces for use in containers or other devices whose surfaces contact the products, compositions, precursors, or intermediates during manufacture, packaging, and distribution of biopharmaceutical products that are compatible with a variety of biological materials and / or biopharmaceutical products and their precursors or intermediates. [Background technology]
[0004] A biopharmaceutical product or biological product is a pharmaceutical product produced from or containing components of a living organism. Biopharmaceutical products can include proteins that control the activity of other proteins and cellular processes, genes that control the production of proteins or are therapeutically useful in themselves, proteins that are biologically or immunologically active in living organisms, including plants, microorganisms, viruses, and animals, including humans, or cells that produce substances that suppress or activate components of the immune system or are therapeutically useful in themselves. Types of biopharmaceutical products in this disclosure include cells, proteins (including antibodies, hormones, and enzymes), nucleic acids (including DNA, RNA, and antisense oligonucleotides), vaccines, antibiotics, blood, blood components, allergens, genes, and tissues. Finally, biopharmaceutical products are used to treat diseases and conditions, such as cancer, rheumatoid arthritis, shingles, and Crohn's disease.
[0005] Biopharmaceutical products are typically made using complex manufacturing processes that require genetically engineered living cells that must be frozen for storage, thawed to minimize damage, and grown in reaction vessels or bioreactors. Living cells from which the biopharmaceutical products of the present disclosure can be produced include, for example, microbial cells (e.g., E. coli or yeast cells), mammalian cell lines, plant cell cultures, moss, and other plants. The cells are typically grown in bioreactors of various configurations. Once produced in the cells, the desired biopharmaceutical products must be separated from the cultured cells that produced them and / or the medium into which they are secreted, and purified, all without damaging their complex and fragile structures and without microbial contamination (e.g., by bacteria, viruses, mycoplasma, cell debris, etc.).
[0006] Large-scale biopharmaceutical manufacturing is usually carried out in a series of connected vessels, with upstream and downstream components at the front end. For an overview of the biopharmaceutical manufacturing process, see Jozala AF et al. Brazilian J. of Microbiology 47S (2016) 51-63; Hong MS et al., Computers and Chem Engg. 110 (2018) 106-114 and Hughes B. and Hann LE, Biologics in General Medicine, (2007), Chapter 7. The upstream process is defined as the entire process from initial cell isolation and culture, through cell banking and expansion of the cells, to the final harvest (termination of the culture and collection of the live cell batch, medium and desired product). In the upstream process, cells or cell lines (cell cultures) are first grown in bioreactors. Bioreactors support a wide range of applications, including fermentation, stem cell growth, strain selection and cell line optimization, bioprocess development, initial cell screening and medium selection. After the desired cells and a desired density of cells are produced in culture, they are cultured to produce a desired product, e.g., a biopharmaceutical product. The product may be secreted by the cells into the medium, may remain intracellular, or may be the cell itself. In each case, the product is transferred to downstream processes to obtain a purified biopharmaceutical product having the desired quality or therapeutic activity.
[0007] The downstream part of a bioprocess refers to the part where the cell mass and / or medium from the upstream process is processed to meet the purity and quality requirements for delivering a biopharmaceutical product in the treatment of a disease or condition. Typical downstream processing steps usually include: (a) Biomass separation: Separation of the biomass (microbial cells) is generally performed by centrifugation or ultracentrifugation. If the product is the biomaterial itself, it is collected for processing and the spent medium is discarded. If the product is extracellular, the biomass is discarded. Ultrafiltration is another option to centrifugation. (b) Cell disruption: If the desired product is intracellular, the cellular biomass can be disrupted so that the product is released. The solid-liquid is usually separated by centrifugation or filtration and the cell debris is discarded. (c) Concentration of the broth: The spent medium containing the extracellular product or the medium containing the released product is concentrated. (d) Initial purification: According to the physicochemical properties of the desired product, several methods can be used for the recovery of the product, such as precipitation or chromatography, from, for example, the clarified fermentation broth or medium containing the biopharmaceutical product. (e) Dehydration: When there is a small amount of product in a very large volume of medium, the volume is reduced by removing the medium to concentrate the product. This is often done by vacuum drying or reverse osmosis. (f) Final purification: This is the final step to bring the product to 98-100% purity. The purified biological product is then usually stored in bulk before being formulated in a filling facility for final distribution to the consumer. During formulation or filling, an aliquot of the bulk material is usually mixed with inactive ingredients called excipients. The formulated product is then packaged in containers (e.g., syringes or bags) that are used to deliver the product to subjects in need and sent to market for use by the consumer.
[0008] Each of the above steps requires a container / connector having a surface that contacts the biopharmaceutical product (e.g., a biopharmaceutical product, and / or its precursors and intermediates, and / or a fluid containing live biological material or cells that has been used to manufacture the biopharmaceutical product or is itself a biopharmaceutical product). For some of the containers or connectors, the contact period with the biopharmaceutical product is short. For others, the contact period may be longer, i.e., days or weeks, and for still others, such as bulk storage and delivery devices, the contact period may be several months. Furthermore, biopharmaceutical products may come into contact with various surfaces throughout the course of their manufacture, packaging and delivery. For example, one manufacturer may supply a bioreactor or roller bottles or single-use bags in which the cells that result in the biopharmaceutical product are cultured, another manufacturer may supply the bulk containers used to store the biopharmaceutical product, and another manufacturer may supply vials or bags, or pre-filled syringes for packaging the biopharmaceutical product for delivery to a subject. Each different surface that comes into contact with the biopharmaceutical product can contaminate the material, interact undesirably with the material, or otherwise have an unintended effect on the biological activity of the biopharmaceutical product. Additionally, material can adhere to the walls of various containers and / or connectors, resulting in reduced yields or variable quantities of biomaterial product to be delivered to subjects for the treatment of diseases and conditions.
[0009] This is especially problematic with the increased use of single-use systems, including plastic containers. The biopharmaceutical industry has been moving away from large, fixed tank facilities to more flexible equipment, such as single-use vessels, in the manufacture of biopharmaceutical products in recent years. Single-use systems can save space, allow greater flexibility in scale and space planning, and minimize clean-up costs during development and modification. Scott Rudge, European Pharmaceutical Review, Article 50692 (2018). However, single-use vessels, which are mostly made from plastic, can leach chemicals into process solutions during biopharmaceutical product manufacturing. There can also be some extractables, or leachables, when single-use equipment is heated or comes into contact with solvents (Monika Mahajani, SDI Blog (2019)). All product contact surfaces can also release extractables into the process, affecting the biomaterials or biopharmaceutical products being manufactured, packaged, and distributed. Cell lines used in the manufacture of biopharmaceutical products can be particularly vulnerable to extractables and leachables (collectively, E&L). For example, some cell lines are susceptible to the cytotoxic leachate bis(2,4-di-tert-butylphenyl)phosphate (bDtBPP) from plastic container interface surfaces (Hammond M, et al. PDA J. Pharm. Sci. Technol. 67(2)2013:123-134), and other cell lines are susceptible to the hormone-like effects of some slip agents at interface surfaces (Tappe A et al; Bioprocess International Jan 13,2016).
[0010] Thus, each different surface that comes into contact with a biopharmaceutical product during manufacturing, packaging, and distribution presents the potential to (a) contaminate the product (such as elemental impurities from E&L or plastic materials), (b) cause product instability (such as when proteins adsorb onto contact surfaces and degrade), (c) reduce the quantity and quality of the product, (d) shorten the shelf life of the product, (e) cause unintended effects on biological activity (such as silicone oil resulting in protein aggregation), and (f) cause variation in product potency / quality / quantity / purity across batches of product that move across containers with different contact surfaces.
[0011] In biopharmaceutical manufacturing, purchasing and distribution processes, regulatory agencies require risk assessments to be performed for E&L from all contact points, including factors such as the nature of the extractable species, the process fluid, contact time and contact temperature (see Smithers Rapra E&L Conference News; Introduction to Extractables and Leachables Testing (2015)). Preparing these E&L assessments for each different surface can be a time-consuming process. These times are exacerbated for containers where shelf life and long-term storage are critical.
[0012] The FDA and other regulatory agencies around the world also provide good manufacturing practice (GMP) guidelines for the manufacture of biopharmaceutical products under an appropriate system of quality control. See, for example, Q7 Good Manufacturing Practice Guidelines for Active Pharmaceutical Ingredients (APIs); FDA Document 71518 (2016) and Document 112426 (2018). Compliance with the regulatory guidelines requires careful validation of all processes and equipment used in the manufacture, packaging and distribution of biopharmaceutical products. Therefore, the use of a wide range of containers with different contact surfaces during the manufacturing, packaging and distribution process of biopharmaceutical products can significantly delay the process of obtaining regulatory approval for the manufacture, packaging and distribution of biopharmaceutical products.
[0013] Additionally, any modifications to the manufacturing process, including changes in equipment and materials, or deviations from established protocols that may affect product quality and / or process reproducibility must be verified to ensure that there is no adverse effect on the suitability of the material for use. In this regard, for example, GMP guidelines provide for "Change Control," where any changes to the manufacturing process require regulatory submission and prior agency approval. See, for example, Quality Systems Approach to Pharmaceutical CGMP Regulations; FDA Document 71023 (2006) and Pharma Change Control; The Executive Briefing Series; FDA News (2013). Changes in manufacturing processes and equipment may also result in delayed production times if equipment with different materials must be separately evaluated and validated to comply with the guidelines.
[0014] Preferred biopharmaceutical products of the present disclosure are proteins, such as therapeutic proteins, and antibodies. The amino acid interactions that allow such proteins and antibodies to fold and cause a therapeutic effect in the body also result in undesirable adsorption of proteins to surfaces with which they may come into contact and interact. Protein adsorption can lead to irreversible denaturation and aggregation. Other preferred biopharmaceutical products of the present disclosure are biomaterials, such as cells useful in cell-based therapy. These biomaterials can also be affected by the surfaces they come into contact with. Yet other biopharmaceutical products of the present disclosure can be nucleic acids, including DNA, RNA, and antisense oligonucleotides. They can also be affected by the surfaces they come into contact with. Summary of the Invention [Problem to be solved by the invention]
[0015] Therefore, there is a need to minimize the different surfaces that biopharmaceutical products, their intermediates and precursors come into contact with in order to reduce possible problems with product potency, quality, purity, shelf life, etc. There is also a need to optimize and harmonize the upstream and downstream processes involved in the manufacture, packaging and distribution of biopharmaceutical products in order to produce high yield, high quality, high purity products in a timely and cost-effective manner. The immediate benefit of biopharmaceutical product manufacturing, packaging and distribution systems with common contact surfaces is the reduction in the time required for validation of these systems by regulatory agencies, and therefore a faster and more efficient route to market for the final product. Furthermore, there is a need to customize the surfaces that come into contact with a particular biopharmaceutical product, its intermediates and precursors, in order to improve the compatibility of the surfaces with the product and to reduce or avoid other effects resulting from the surface contact of the biopharmaceutical product along with denaturation or adsorption or both. [Means for solving the problem]
[0016] In one aspect, a system of the disclosure comprises at least two containers or connectors for use in the manufacture, packaging or distribution of a biopharmaceutical product, each of said containers comprising a wall defining an internal cavity, the containers optionally being open or openable at one end or side, each wall of said containers having an interior surface facing the cavity, the interior surface being characterized by a common surface present on the wall in substantially all areas where the interior surface contacts the biopharmaceutical product, the common surface comprising a tie coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bonding coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bonding coating or layer has an exterior surface facing the wall of the container and an interior surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer has an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y where x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and has an inner surface facing the cavity.
[0017] In a preferred embodiment of the present disclosure, the at least two containers include a first container useful for holding a bulk quantity of a biopharmaceutical product and a second container useful for administering an aliquot of that bulk quantity to a subject in need.
[0018] In other preferred embodiments, the at least two containers comprise containers useful in the cultivation of cells for the production of a biopharmaceutical product.
[0019] In other embodiments of the present disclosure, the at least two containers / connectors include most, or preferably all, of the containers / connectors useful in culturing cells to produce a biopharmaceutical product. In other embodiments, the at least two containers / connectors include most, or preferably all, of the containers / connectors useful in culturing cells to produce a biopharmaceutical product and most, or preferably all, of the containers / connectors useful in bulk storage of those products and packaging them for delivery to a subject in need.
[0020] The disclosed system has several advantages. These advantages include, for example, a common interface between at least two of the containers and / or connectors, which can reduce possible problems with the yield, quality, purity and potency of the biopharmaceutical product. The common interface between at least two, and preferably more, of the containers and connectors can reduce the time required to validate each interface and for the interface to be approved by a regulatory agency (such as the FDA). This allows for a faster path to market approval for the biopharmaceutical product. Thus, the disclosed system provides a novel solution to improve the effectiveness of the biopharmaceutical product manufacturing, packaging and distribution process while ensuring the production of high yield, high quality biopharmaceutical products.
[0021] Particular embodiments of the present disclosure are set forth in the following numbered paragraphs. 1. A system comprising at least two containers or connectors for use in the manufacture, packaging or distribution of a biopharmaceutical product, each of said containers comprising a wall defining an internal cavity, the containers being optionally open or openable at one end or side, each wall of said containers having an interior surface facing the cavity, the interior surface being characterized by a common surface present on the wall in substantially all areas where the interior surface contacts the biopharmaceutical product, the common surface comprising a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bonding coating or layer is SiO x Cy or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bonding coating or layer has an outer surface facing the wall of the container and an inner surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer has an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and an inner surface facing the cavity.
[0022] 2. The container may be a 384-well plate, a 96-well plate, a bioreactor, a blood collection tube, a bottle, a bulk storage container, a cannula, a capture column, a cartridge, a catheter, a cell bank vial, a cell separator, a cell vial, a centrifugal pump, a centrifuge tube, a chromatography column, a chromatography vial, a clarifier, a sealed container, a container stopper system, a cryopreservation container, a culture bottle, a shipping container, a diafiltration device, a dispensing unit, an ELISA plate, an elution bag, a vacuum blood collection tube, a fill / finish device, a filtration device, a freeze dryer, a collection container, a shaker, an in-process analytical device, an intermediate column, an intravenous (IV) bag, a media bag, a media bottle, a media container, a membrane chromatography column, a microplate, a microtiter plate, a microwell plate, a mixing bag, a monitoring device, a multi-purpose 13. The system of paragraph 1, wherein the bioreactor is selected from the group consisting of one or more of: a primary bioreactor, a package filling device, a pump, a Petri dish, a pipette tip, a plate, a plunger, a polished column, a prefilled syringe, a prefilled syringe with luer lock fitting, primary packaging, a production bioreactor, a production fermenter, a roller bottle, a sampling tube, a sampling container, a seed fermenter, a separator, a shake flask, a single use bioreactor, a slide, a spinner flask, a fixed needle prefilled syringe, a storage bag, a sterilizer, a stock culture vial, a storage container, a syringe (prefilled), a tank, an end reactor, a transport bag, an ultrafiltration / diafiltration device, an ultrafiltration device, an upstream bioreactor, a valve, a vial, a viral filtration device, a viral inactivation container, and a wave bioreactor.
[0023] 3. The system of paragraph 2, wherein at least one of the containers is selected from the group consisting of a bioreactor, a pump, a cell bank vial, a harvest container, a stock culture vial, a fermenter, a shake flask, a shaker, a column, a separator, a bag, a beaker, a tank, a cylinder, a bulk storage unit or container, a single-use bag, a roller bottle, a storage tube, and a sample collection container.
[0024] 4. The system of paragraph 2, wherein at least one of the containers is selected from the group consisting of a syringe, a dispensing unit, a vial, and an intravenous (IV) bag.
[0025] 5. The system of any one of paragraphs 1-4, wherein the at least two containers include (a) a first container useful for holding a bulk quantity of a biopharmaceutical product, and (b) a second container useful for administering a composition comprising at least a portion of said biopharmaceutical product to a subject in need thereof.
[0026] 6. The system of paragraph 5, further comprising one or more connectors connecting one or more of the containers to one or more other containers or connectors, wherein at least one of said containers in one or more series has a wall, the inner surface of which is characterized by a surface present on the wall in substantially all areas that contact the biopharmaceutical product being manufactured, said surface being common to the innermost surfaces of the first container and the second container.
[0027] 7. The system of paragraph 6, wherein one of the vessels in the one or more series of vessels is independently selected from the group consisting of a bioreactor, a fermenter, a pump, a roller bottle, a flask, a shaker, a separator, a bag, a beaker, a sampling vessel, a cylinder, a pipette tip, a slide, and a vial.
[0028] 8. The system of paragraphs 6 or 7, wherein at least one of the containers in the one or more series of containers is connected to another of the containers in the one or more series of containers via one or more connectors, at least one of the connectors comprising a wall defining an internal cavity, the wall having an interior surface characterized by a surface present on the wall in substantially all areas in contact with the biopharmaceutical product being manufactured, the surface being common to the innermost surfaces of the first container and the second container.
[0029] 9. The system of paragraph 8, wherein each connector is independently selected from the group consisting of tubing, piping, valves, and pipes.
[0030] 10. The system of paragraph 5, further comprising one or more series of containers useful in the production of said bulk quantities of said biopharmaceutical product, wherein at least one of said containers in the series or series has a wall, the inner surface of which is characterized by a surface present on the wall in substantially all areas that contact the biopharmaceutical product being produced, said surface being not common to a surface of the first container and said second container, and wherein the surface present on the wall in substantially all areas that contact the biopharmaceutical product being produced is common to a surface on the wall of at least one other of said containers in the series or series.
[0031] 11. The common surface comprises a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bonding coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bonding coating or layer has an outer surface facing the wall of the container and an inner surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer has an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y 11. The system of paragraph 10, wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and an inner surface facing the cavity.
[0032] 12. A system comprising at least two containers or connectors useful for evaluating one or more characteristics of a biopharmaceutical product, namely one or more of quality, purity and integrity, each of said containers comprising a wall defining an internal cavity, the containers being optionally open or openable at one end or at one side, each wall of said containers having an inner surface facing the cavity, the inner surface being characterized by a common surface present on the wall in substantially all areas where the inner surface contacts the biopharmaceutical product, the common surface comprising a binding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bonding coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bonding coating or layer has an outer surface facing the wall of the container and an inner surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer has an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and an inner surface facing the cavity.
[0033] 13. The system of paragraph 12, wherein the common surface is not identical to the common surface of the first and second containers of paragraph 5, the common surface of one or more containers of paragraph 9, or any of the above.
[0034] 14. The system of paragraph 12, wherein the common surface is identical to one or both of the common surface of the container and the second container of paragraph 5 and the common surface of the one or more containers of paragraph 9.
[0035] 15. The system of paragraphs 11 or 12, wherein each container is selected from the group consisting of a microplate, a microtiter plate, a microwell plate, and a Petri dish.
[0036] 16. The system of any of paragraphs 1-15, wherein the biopharmaceutical product is selected from the group consisting of one or more of an antibody, a bulk biopharmaceutical formulation, a cell culture formulation, a cell suspension, a culture medium, a biopharmaceutical product, a biopharmaceutical substance, a biopharmaceutical formulation, an expression vector / host formulation, a harvested cell formulation, a host cell composition, a host cell contaminant, a mobile phase, a monoclonal antibody formulation, a product stream, a seed train composition, a stationary phase, a peptide or protein formulation, and a nucleic acid formulation.
[0037] 17. A method of manufacturing a system comprising at least two containers or connectors useful in the manufacture, packaging or distribution of a biopharmaceutical product, each of said containers or connectors comprising a wall defining an internal cavity, said containers or connectors optionally being open or openable at one end or at one side, and each wall of said containers or connectors having an interior surface facing the cavity, comprising: Providing a biopharmaceutical product; providing a temporary contact surface; determining whether the biopharmaceutical product is compatible with the temporary contact surface; - modifying the temporary interface to improve its compatibility with the biopharmaceutical product, thereby producing a customized interface; using a customized contact surface to manufacture a system such that an interior surface of the container / connector is characterized by a customized common surface present on the interior surface in substantially all areas where the interior surface contacts the biopharmaceutical product, the customized common surface including a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bonding coating or layer is SiO x C y or SiNx C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bonding coating or layer has an outer surface facing the wall of the container and an inner surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer has an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and an inner surface facing the cavity; A method comprising:
[0038] 18. The method of paragraph 17, wherein the biopharmaceutical product is selected from the group consisting of one or more of an antibody, a bulk biopharmaceutical preparation, a cell culture preparation, a cell suspension, a culture medium, a biopharmaceutical product, a biopharmaceutical substance, a biopharmaceutical preparation, an expression vector / host preparation, a harvested cell preparation, a host cell composition, a host cell contaminant, a mobile phase, a monoclonal antibody preparation, a product stream, a seed train composition, a stationary phase, a peptide or protein formulation, and a nucleic acid formulation.
[0039] 19. The method of paragraph 17 or 18, wherein the tentative contact surface has a water contact angle of less than 90°.
[0040] 20. The method of any of paragraphs 17-19, wherein the tentative contact surface has less than 1% H-bond donor groups as determined by X-ray photoelectron spectroscopy (XPS) and optionally hydrogen forward scattering (HFS) analysis or Rutherford backscattering (RBS) analysis.
[0041] 21. The method of any of paragraphs 17-20, wherein the tentative contact surface has at least 1% H-bond acceptor groups as determined by XPS and optionally HFS or RBS analysis.
[0042] 22. The method of any of paragraphs 17-21, wherein the temporary contact surface has less than 1% anionic and cationic groups as determined by XPS.
[0043] 23. The method of any of paragraphs 17-22, wherein the tentative contact surface is substantially free of metal or metalloid atoms other than silicon, as determined by XPS.
[0044] 24. The method of any of paragraphs 17-23, wherein the temporary contact surface is a plasma (enhanced) chemical vapor deposition (PECVD) coating.
[0045] 25. The method of any of paragraphs 17-24, wherein the tentative contact surface has the following statistical ratios of silicon, oxygen, carbon and hydrogen atoms as determined by XPS and optionally HFS or RBS: Si=1:O=x:C=y:H=z, where x is from about 1.5 to about 2.9, y is from about 0 to about 1, and z is in the range of from about 0 to about 4.
[0046] 26. The method of any of paragraphs 17-24, wherein the tentative contact surface has the following statistical ratios of silicon, oxygen, carbon and hydrogen atoms as determined by XPS and optionally HFS or RBS: Si=1:O=x:C=y:H=z, where x is 0.5-2.4, y is 0.6-3 and z is 2-9.
[0047] 27. The method of any of paragraphs 17-24, wherein the tentative contact surface has the following statistical ratios of silicon, oxygen, carbon and hydrogen atoms as determined by XPS and optionally HFS or RBS: Si=1:O=x:C=y:H=z, where x is 1.5-2.9, y is about 0 and z is about 0.
[0048] 28. The container is a 384-well plate, a 96-well plate, a bioreactor, a blood collection tube, a bottle, a bulk storage container, a cannula, a capture column, a cartridge, a catheter, a cell bank vial, a cell separator, a cell vial, a centrifugal pump, a centrifuge tube, a chromatography column, a chromatography vial, a clarifier, a sealed container, a container stopper system, a cryopreservation container, a culture bottle, a shipping container, a diafiltration device, a dispensing unit, an ELISA plate, an elution bag, a vacuum blood collection tube, a fill / finish device, a filtration device, a freeze dryer, a collection container, a shaker, an in-process analytical device, an intermediate column, an intravenous (IV) bag, a media bag, a media bottle, a media container, a membrane chromatography column, a microplate, a microtiter plate, a microwell plate, a mixing bag, a monitoring device, a multipurpose vial, 28. The method of any of paragraphs 17-27, wherein the bioreactor is selected from the group consisting of one or more of: a prefilled syringe, a package filling device, a pump, a Petri dish, a pipette tip, a plate, a plunger, a polished column, a prefilled syringe, a prefilled syringe with luer lock fitting, primary packaging, a production bioreactor, a production fermenter, a roller bottle, a sampling tube, a sampling container, a seed fermenter, a separator, a shake flask, a single use bioreactor, a slide, a spinner flask, a fixed needle prefilled syringe, a storage bag, a sterilizer, a stock culture vial, a storage container, a syringe (prefilled), a tank, an end reactor, a transport bag, an ultrafiltration / diafiltration device, an ultrafiltration device, an upstream bioreactor, a valve, a vial, a virus filtration device, a virus inactivation container, and a wave bioreactor.
[0049] 29. A method for producing a customized contact surface by modifying a temporary contact surface of a container to improve its compatibility with a particular biopharmaceutical product, comprising: Reducing the water contact angle of the temporary contact surface by about 10% to 90% of the original water contact angle; reducing the proportion of H-bond donor groups at the tentative interface by about 10% to 90%, as determined by XPS analysis and optionally HFS or RBS analysis; increasing the proportion of H-bond acceptor groups at said tentative interface by about 10% to 90%, as determined by XPS analysis and optionally HFS or RBS analysis; reducing the percentage of anionic groups, cationic groups, or both, at the tentative contact surface by about 10% to 90% as determined by XPS analysis; reducing the percentage of metal or metalloid atoms other than silicon at the tentative contact surface by about 10% to 90% as determined by XPS analysis; Any of the methods of paragraphs 17 to 28, including at least one of the following:
[0050] Further aspects of the present disclosure will become apparent from the description and claims herein. [Brief description of the drawings]
[0051] [Figure 1a] The amount of IgG protein (ng / cm2) adsorbed to the contact surface of coated polymer tubes (2-ply and 3-ply in this disclosure) and an uncoated polymer, cyclic olefin polymer (COP) vessel, is compared. [Figure 1b] The amount of IgG protein (ng / cm2) retained on the contact surface of coated polymer tubes (2-ply and 3-ply in this disclosure) and an uncoated polymer, cyclic olefin polymer (COP) container is compared. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0052] definition In order to make the present disclosure easier to understand, some terms are first defined. These definitions should be read in light of the remainder of the present disclosure and as understood by those skilled in the art. Unless otherwise defined, all technical and chemical terms used herein have the same meaning as commonly understood by those skilled in the art. Additional definitions are provided throughout the above detailed description.
[0053] Exemplary methods and materials are described herein, although methods and materials similar or equivalent to those described herein can also be used in the practice or testing of various aspects and embodiments. The materials, methods, and examples are illustrative only and are not intended to be limiting.
[0054] The word "comprising" according to any embodiment does not exclude other elements or steps. The indefinite article "a" or "an" does not exclude a plurality, unless otherwise indicated. The singular includes the plural.
[0055] Whenever a parameter range is given, it is intended to disclose the parameter values given as the limits of the range and all values of the parameter that fall within that range.
[0056] Reference herein to "about" a value or parameter includes (and states) an embodiment directed to that value or parameter itself. For example, a reference to "about X" includes the description of "X." The term "about" as used herein allows for a variation of ±10% within the range of significant figures.
[0057] When aspects or embodiments are described in terms of a Markush group or other classification of alternatives, the present disclosure encompasses not only the entire group recited as a whole, but also each member of the group individually, and all possible subgroups of the main group, and also the main group lacking one or more of the group members. The present disclosure also contemplates the explicit exclusion of any one or more of the group elements, or the inclusion of other elements not recited in the Markush group.
[0058] The term "system" as used herein refers to a set of containers / connectors or several sets of containers / connectors that work together in the manufacturing, packaging and / or distribution of a biopharmaceutical product. The system may also include a set of containers / connectors useful for testing the manufacturing process and / or the quality of a biopharmaceutical product manufactured using the process, including testing the quality of the biopharmaceutical product during and after packaging and storage. The system includes containers / connectors, each having a surface that contacts the biopharmaceutical product and / or its intermediates or precursors. In some embodiments, the system includes two or more of the containers / connectors used in upstream processes in a biopharmaceutical product manufacturing process. In some embodiments, the system includes two or more of the containers / connectors useful in upstream processes in a biopharmaceutical product manufacturing process. In some embodiments, the system includes two or more of the containers / connectors necessary in the quality control of a biopharmaceutical product manufacturing, packaging and distribution process. In still other embodiments, the system includes two or more of the containers / connectors useful in any combination of upstream and downstream processes in a biopharmaceutical product manufacturing, packaging and distribution process, as well as two or more of the containers / connectors used in the quality control of the process and its various stages.
[0059] The term "container" as used herein may be any type of article used in the manufacture, packaging, distribution and / or quality control of a biopharmaceutical product. A container comprises a wall that defines an internal cavity. A container in the context of this disclosure is or can be open, optionally at one end or on one side. The wall of each container has an inner surface that faces the cavity, the inner surface being characterized by one surface being present on the wall in substantially all areas where the inner surface contacts the biopharmaceutical product. A container / connector in the context of this disclosure may have one or more openings, e.g., one opening or two openings. A container may have rigid or flexible walls or a combination of both. Rigid containers may be made of stainless steel or the like, such as stainless steel bioreactors or glass or metal roller bottles. Flexible containers may be single-use disposable bags only, such as plastic bioreactors or storage bags, or may be used with containers having rigid or flexible walls.
[0060] In some embodiments, the series of vessels in an upstream process includes any vessel that comes into contact with the biopharmaceutical product or precursors thereof, and any fluid solvents, media, and the like.
[0061] Some non-limiting examples of containers of the present disclosure include 384 well plates, 96 well plates, bioreactors, blood collection tubes, bottles, bulk storage containers, cannulas, capture columns, cartridges, catheters, cell bank vials, cell separation devices, cell cials, centrifugal pumps, centrifuge tubes, chromatography columns, chromatography vials, clarifiers, sealed containers, container stopper systems, cryopreservation containers, culture bottles, shipping containers, diafiltration devices, ELISA plates, elution bags, vacuum blood collection tubes, fill / finish devices, filtration devices, freeze dryers, collection containers, shakers, in-process analytical equipment, intermediate columns, intravenous (IV) bags, media bags, media bottles, media containers, membrane chromatography columns, microplates, microtiter plates, microwell plates, mixing bags, monitoring devices, multipurpose bioreactors, package filling devices, pumps, petri dishes, pipette tips , plate, plunger, polish column, prefilled syringe, prefilled syringe with luer lock fitting, primary packaging, production bioreactor, production fermenter, roller bottle, sampling tube, sampling container, seed fermenter, separator, shake flask, single use bioreactor, slide, spinner flask, fixed needle prefilled syringe, storage bag, sterilizer, stock culture vial, storage container, syringe (prefilled), tank, end reactor, transport bag, ultrafiltration / diafiltration device, ultrafiltration device, upstream bioreactor, valve, vial, virus filtration device, virus inactivation container or wave bioreactor.
[0062] As used herein, the terms "biopharmaceutical product", "biopharmaceutical product" and the like refer to therapeutic or prophylactic agents or products made from or containing components of a living organism (biomaterial) and / or by means involving extraction from native (unmanipulated) biological sources and their precursors and intermediates, including proteins (including antibodies, hormones and enzymes), nucleic acids (including DNA, RNA and antisense oligonucleotides), vaccines, antibiotics, blood, blood components, cells, allergens, genes and tissues. Such products can be used for therapeutic, prophylactic or diagnostic purposes. As used herein, the term "biomaterial" (as part of a biopharmaceutical product) refers to raw materials (including solvents, media, mobile phases, stationary phases, etc.), cells, cell lines, cell suspensions, inocula, seed trains, product streams, cell cultures, expression vectors / host preparations, harvested cells, host cell compositions, host cell contaminants, biomass, etc., used to make a biopharmaceutical product, and the biomaterial itself when used, for example, in cell-based therapies.
[0063] The term "surface" as used herein refers to an interior surface of a container / connector that contacts a biopharmaceutical product. In particular, the containers / connectors of the present disclosure comprise walls that define an internal cavity, and the containers / connectors are or can be open, optionally at one end or on one side. Each wall of said containers / connectors has an interior surface that faces the cavity, and the interior surface is characterized by a surface that is present on the wall in substantially all areas where the interior surface contacts a biopharmaceutical product.
[0064] As used herein, the term "common surface" refers to an interior surface of a container / connector that is identical to the interior surface of at least one other container / connector used in the manufacturing, packaging and distribution of a biopharmaceutical product.
[0065] Terminology relating to the various coatings or layers, i.e., bond coatings or layers, barrier coatings or layers, and pH coatings or layers, and methods of creating and applying the coatings or layers, for example, by plasma enhanced chemical vapor deposition (PECVD), are described in U.S. Patent Application Publication No. 2018-0334545A1, such as U.S. Pat. Nos. 10,016,338, 9,937,099, and 9,554,968 for three-layer PECVD coatings, as well as U.S. Pat. Nos. 9,878,101, 9,863,042, and 9,554,968 for PECVD coatings. Nos. 9764093, 9458536, 9272095 (hydrophobicity) and 7985188, for example U.S. Pat. No. 9662450 for plasma treatment of polymer surfaces, U.S. Pat. No. 9545360 for sugar protective coatings for pharmaceutical packaging, for example U.S. Patent Application Publication No. 2015-0297800A1 for pharmaceutical packaging, PCT Application PCT / US2020 / 012638 for flexible bags, and U.S. Provisional Patent Application No. 62 / 929,668 for blood collection tubes, each of which is incorporated herein by reference in its entirety.
[0066] The term "connector" as used herein refers to an instrument that provides a reliable connection and fluid transfer, typically sterile, between two separate process components or containers in a biopharmaceutical manufacturing operation. Connectors may be male or female and may be suitable for single or multiple use. Connectors may be used to connect two rigid containers to each other, two flexible containers to each other, or a rigid container to a flexible container. Connectors may be tubing, tubing, valves, pipes, etc. See, for example, Proctor G, Parker Bioprocess Filtration Team report (October 15, 2019) for various types of connectors.
[0067] Metalloids other than silicon as used in this disclosure are boron, germanium (Ge), arsenic (As), antimony (Sb), tellurium (Te) and astatine (At). As used herein, a metal is any of the commonly recognized metallic elements, including but not limited to alkali metals, alkaline earth metals, transition metals, lanthanides and actinides.
[0068] As used herein, the term "upstream processing" in biopharmaceutical product manufacturing, packaging and distribution processes refers to typical bioprocessing stages where cell lines are developed and biomass is generated on a significant scale. Upstream processing is the growth of either bacterial culture-based or cell culture-based products, referred to as bacterial fermentation or mammalian cell culture, respectively. In the upstream process, an inoculum is created (by isolating and purifying cells), a growth medium is created, and the growth rate is increased for large-scale product generation. Once an appropriate cell density is reached, the culture is transferred to the downstream process. In commercial production, the upstream process can be carried out in one or more vessels (such as bioreactors) with volumes ranging from 1,000 L to 10,000 L. Seed cultures are typically grown in a series of passes before inoculating these large manufacturing vessels.
[0069] In upstream processes, the interface surfaces within the vessels may come into contact with biopharmaceutical products (including intermediates or precursors thereof) and / or biomaterials that are used to generate biopharmaceutical products or are themselves biopharmaceutical products. For example, precursors of protein biopharmaceutical products can be unfolded proteins, polypeptides, unprocessed proteins with or without partial post-processing chemical modifications, intermediate forms of proteins, etc. Biomaterials can be cells, cell inocula, cell cultures, cell lines, biomass, etc. Examples of vessels in one or more series of vessels used in upstream processes include bioreactors, fermenters, pumps, roller bottles, flasks, shakers, columns, separators, bags, beakers, sampling vessels, cylinders, pipette tips, slides, vials, etc.
[0070] As used herein, the term "downstream processing" in biopharmaceutical product manufacturing, packaging and distribution processes typically includes the following non-limiting steps: (a) Insoluble removal: the product is captured as a solute in a particle-free liquid, e.g., separation of cells, cell debris or other particulate matter from a fermentation broth containing an antibiotic. Typical operations to achieve this are filtration, centrifugation, sedimentation, settling, flocculation, electroprecipitation and gravitational settling. Further operations such as grinding, homogenization or leaching can be used to recover the product from solid sources such as plant and animal tissues. (b) Product isolation is the removal of components whose properties differ significantly from the desired product. For most products, water is the major impurity and the isolation steps are designed to remove most of it, reducing the volume of material to be manipulated and concentrating the product. Product isolation operations include solvent extraction, adsorption, ultrafiltration and precipitation steps, which are some of the unit operations. (c) Product purification is performed to separate contaminants similar to the product in physical and chemical properties. As a result, the steps of this stage are expensive to perform and require sensitive and sophisticated equipment. This stage represents a significant portion of the overall downstream processing costs. Examples of purification operations include affinity, size exclusion, reverse phase chromatography, ion exchange chromatography, crystallization and fractional precipitation. (d) Product final purification refers to the final downstream processing step, which ends with the packaging of the product in a form that is stable, easily transportable and convenient. Typical operations include crystallization, dehydration, freeze drying and spray drying. Depending on the product and its intended use, final purification can also include operations to sterilize the product and remove or inactivate contaminants and viruses that may compromise the safety of the product. Such operations can include virus removal or depyrogenation.
[0071] All cited references are incorporated in their entirety for any purpose (in the case of conflict, the present specification will control).
[0072] Detailed Description The present disclosure will now be described more fully in some embodiments. However, the present disclosure can be embodied in many different forms and should not be construed as being limited to the embodiments shown herein. Rather, these embodiments are examples. Each embodiment described herein can be used individually or in combination with any other embodiment described herein.
[0073] Downstream Biopharmaceutical Manufacturing, Packaging and Distribution Systems One aspect of the present disclosure is a system comprising two or more containers that include a common contact surface that can be used in downstream processes for manufacturing, packaging and distribution of biopharmaceutical products.
[0074] In some embodiments of this aspect of the disclosure, the system of the disclosure comprises at least a first container for holding a bulk quantity of a biopharmaceutical product and a second container useful for administering a composition comprising at least a portion of said biopharmaceutical product to a subject in need. Examples of the first container are tanks, cylinders, bulk storage units or containers, single-use bags, roller bottles, storage tubes, etc. Examples of the second container are syringes, dispensing units, bags, vials, intravenous (IV) bags, etc.
[0075] Each of the containers in this exemplary embodiment comprises a wall defining an internal cavity, the containers are optionally open or open at one end or side, the wall of each of said containers having an interior surface facing the cavity, the interior surface being characterized by a common surface present on the wall in substantially all areas where the interior surface contacts the biopharmaceutical product, the common surface including a binding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bonding coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bonding coating or layer has an exterior surface facing the wall of the container and an interior surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer has an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y where x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and has an inner surface facing the cavity.
[0076] In some embodiments, the contact surfaces of some containers and equipment in the downstream process are not characterized by a common contact surface with other containers in the downstream assembly. For example, filters, purification combs, chromatography columns, etc., having chemically modified ligands on their surfaces to capture impurities and / or biopharmaceutical materials, may not have the same contact surface as the contact surfaces present in other containers in the downstream process, such as tanks, cylinders, bulk storage units or containers, single-use bags, roller bottles, storage tubes, syringes, dispensing units, vials, etc. Similarly, other containers in the downstream process may not have a common container. However, in preferred embodiments, multiple containers and connectors used in the downstream process, and possibly most of them, share a common surface.
[0077] Upstream biopharmaceutical manufacturing systems One aspect of the present disclosure is a system comprising two or more vessels containing a common contact surface that can be used in the upstream process of manufacturing a biopharmaceutical product.
[0078] In some embodiments of this aspect of the disclosure, the system of the disclosure comprises one or more series of vessels useful in the manufacture of said biopharmaceutical product, at least one of said vessels in the one or more series having an interior wall, characterized by a surface present on the interior wall in substantially all areas that contact the biopharmaceutical product being manufactured, which surface is common to an innermost surface of another of the vessels and connectors used in the upstream or downstream process. For example, in some embodiments, an upstream process can include one or more series of vessels useful in the manufacture of a biopharmaceutical product, at least one of said vessels in the one or more series having a wall, characterized by a surface present on the interior surface of the wall in substantially all areas that contact the biopharmaceutical product being manufactured, which surface is not common to a surface of any of the vessels or connectors in the downstream process, but the surface present on the wall in substantially all areas that contact the biopharmaceutical product being manufactured is common to a surface of a wall of at least one of another of said vessels in the one or more series of vessels or connectors used in the upstream process. For example, each vessel in a series of vessels in an upstream process (i.e., production vessels or bioreactors) that can be used to grow or harvest cells that result in a desired pharmaceutical product may have the same common contact surface, however, this surface may be different from the contact surface present in the downstream process vessel that holds or delivers the biopharmaceutical product to a subject in need thereof.
[0079] In other embodiments, the common surface is shared by one or more vessels or connectors used in the upstream and downstream processes. In one preferred embodiment, the common surface is shared by one or more of the vessels (e.g., one or more, preferably all, of the bioreactors) used to culture the cells that result in the biopharmaceutical product, and the vessels that store the bulk biopharmaceutical product, and preferably also the vessels used to deliver the biopharmaceutical product to subjects in need. More preferably, the common surface is also shared by the various connectors and other equipment that connect the bioreactors to each other and to the bulk and delivery vessels.
[0080] In the above aspects, the common surface in some embodiments comprises a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer, the bonding coating or layer being SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, the bond coating or layer has an exterior surface facing the wall of the container and an interior surface facing the cavity, and the barrier coating or layer comprises SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer has an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity, and the pH protective coating or layer is SiO x C y or SiN x C y where x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and has an inner surface facing the cavity.
[0081] connector In some embodiments, one or more vessels in an upstream or downstream process can be connected to one another. In still other embodiments, such as in continuous manufacturing, packaging and / or distribution systems, connectors can connect one or more vessels in an upstream process to one or more vessels in a downstream process. In all embodiments, examples of connectors include tubing, piping, valves, pipes, and the like.
[0082] In some embodiments, the connector provides a sterile connection between two processing units. In some embodiments, the connector provides a sterile connection between three or more processing units. For example, a series of containers can be connected to each other via a connector, and the series can have multiple containers. In some embodiments, the connector can connect an array of containers to each other in series. In some embodiments, one or more connectors comprise a wall defining an internal cavity, the wall having an inner surface characterized by a surface present on the wall in substantially all areas that contact a biopharmaceutical, product, intermediate, or process or biological material during manufacturing, the surface being common to the innermost surface of another upstream or downstream process, container, or connector.
[0083] quality control equipment One aspect of the present disclosure is a system comprising one or more series of containers useful for assessing one or more of the following features: (i) the quality, purity and integrity of one or more of the compositions constituting a biopharmaceutical product, (ii) precursors of the biopharmaceutical product, and (iii) biomaterials used to manufacture the biopharmaceutical product, each of said containers comprising a wall defining an internal cavity, the containers optionally being open or openable at one end or at one side, each wall of said container having an inner surface facing the cavity, the inner surface being characterized by a common surface present on the wall in substantially all areas where the inner surface contacts said biopharmaceutical product, the common surface comprising a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer, the bonding coating or layer being SiOx C y or SiN x C y wherein x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, the bond coating or layer has an exterior surface facing the wall of the container and an interior surface facing the cavity, and the barrier coating or layer comprises SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer has an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity, and the pH protective coating or layer is SiO x C y or SiN x C y where x is from about 0.5 to about 2.4, y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and has an inner surface facing the cavity.
[0084] In some embodiments, a system useful for assessing the quality, purity and integrity of a biopharmaceutical product during the manufacturing, packaging and distribution process comprises equipment that maintains quality control over the biomanufacturing process, materials and products. Quality control (QC) and quality assurance (QA) are essential functions of the biopharmaceutical industry that require pharmaceutical companies to thoroughly test materials, processes, equipment, techniques, environment and personnel to ensure that the final product is consistent, safe, effective, predictable and free of defects. QC applications can include trace analysis by FT-IR / Raman microscopy, microbial identification by MALDI-TOF-MS, compound identity determination and quantitative analysis by NMR, raw material analysis by XRD spectroscopy, counterfeit analysis by FT-IR spectroscopy, and analysis of APIs by LC-MS. Examples of containers that can be used for QC testing of biopharmaceutical materials include microplates, microtiter plates, microwell plates, petri dishes, pipette tips, vials, etc.
[0085] In some embodiments of the present disclosure, when aspects of the biopharmaceutical product such as quality, quantity, purity, integrity, etc. are tested, the contact surfaces of the equipment used to test these aspects of the intact cells are identical to the contact surfaces of at least some of the containers in which these cells were grown and harvested. In other embodiments, the contact surfaces of the equipment used to test these aspects of the intact cells are not identical to the contact surfaces of the containers in which these cells were grown and harvested. In some embodiments, when aspects of the biopharmaceutical material (i.e., biopharmaceutical composition and / or its precursors) are tested such as quality, quantity, purity, integrity, etc., the contact surfaces of the equipment used to test these aspects of the biopharmaceutical product are identical to the contact surfaces of at least some of the containers in the downstream process in which the biopharmaceutical product was purified, held, or packaged. In other embodiments, the contact surfaces of the equipment used to test these aspects of the biopharmaceutical product are not identical to the contact surfaces of the containers in the downstream process in which the biopharmaceutical product was purified, held, or packaged.
[0086] Determining the suitability of provisional contact surfaces One aspect of the disclosure is a method of manufacturing, packaging or distributing a biopharmaceutical product, the method comprising the steps of providing a biopharmaceutical product, providing a temporary contact surface, determining whether the biopharmaceutical product is compatible with the temporary contact surface, modifying the temporary contact surface to improve its compatibility with the biopharmaceutical product, thereby producing a customized contact surface, and using the customized contact surface on two or more containers or connectors, each container or connector comprising a cavity and an interior wall, and the interior walls of the two or more containers comprise a customized common surface in the manufacturing, packaging or distribution of the biopharmaceutical product.
[0087] In any embodiment, one or more of the following analytical test methods may be used to determine suitability of the temporary interface.
[0088] Radiolabeled protein adsorption experiments can be performed according to previously published literature, such as the previously cited and incorporated articles written by Mingchao Shen et al., Y. Vickie Pan et al., or TA Horbett. These methods are used in the Examples herein to determine surface adsorption and denaturation of peptides.
[0089] X-ray photoelectron spectroscopy (XPS) can be performed, for example, by using a PHI Quantum 2000 instrument sold by Physical Electronics, Eden Prairie, MN. XPS can be used to determine the non-hydrogen surface atomic composition of plasma-treated microplates or other containers and equipment. The X-ray source used can be monochromated Alkα at 1486.6 eV. The acceptance and exit angles can be ±23° and 45°, respectively. The analysis area can be 1400×300 μm. These conditions are used in the examples herein to determine surface changes and the presence of hydrogen bond donor and acceptor groups.
[0090] Measurement of the water contact angle of a surface can be performed, for example, by placing a 5-10 microliter drop of distilled and deionized water on the surface to be evaluated. The angle formed between the vector at the solid-liquid interface and the vector at the liquid-air interface is measured. These conditions are used in the examples herein.
[0091] The measured water contact angle can be between 0 and 180 degrees. Generally, angles greater than 90 degrees are considered hydrophobic and angles less than 90 degrees are considered hydrophilic. Angles approaching 0 degrees are considered very hydrophilic and angles approaching 180 degrees are considered very hydrophobic.
[0092] Correction of temporary contact surface In some embodiments of this aspect of the disclosure, modifying or customizing the tentative contact surface improves the compatibility of the tentative contact surface with a biopharmaceutical product and includes at least one of the following steps: In some embodiments, modifying the tentative contact surface is performed at least in part by reducing the water contact angle of the tentative contact surface. In other embodiments, modifying the tentative contact surface is performed at least in part by reducing the proportion of H-bond donor groups as determined by X-ray photoelectron spectroscopy (XPS) and hydrogen forward scattering (HFS) analysis of the tentative contact surface. In some embodiments, modifying the tentative contact surface is performed at least in part by reducing the proportion of H-bond donor groups as determined by X-ray photoelectron spectroscopy (XPS) and hydrogen forward scattering (HFS) analysis or Rutherford backscattering (RBS) analysis of the tentative contact surface. Hydrogen forward scattering (HFS) analysis or Rutherford backscattering (RBS) analysis are two different analyses of the hydrogen content of the contact surface. Either or both can be used. In other embodiments, modifying the tentative contact surface is performed at least in part by increasing the proportion of H-bond donor groups as determined by X-ray photoelectron spectroscopy (XPS) and hydrogen forward scattering (HFS) or Rutherford backscattering (RBS) analysis of the tentative contact surface. In some embodiments, modifying the tentative contact surface is performed at least in part by increasing the proportion of H-bond donor groups as determined by X-ray photoelectron spectroscopy (XPS) and Rutherford backscattering (RBS) analysis of the tentative contact surface. In other embodiments, modifying the tentative contact surface is performed at least in part by reducing the proportion of anionic and cationic groups or both as determined by XPS of the tentative contact surface. In yet other embodiments, modifying the tentative contact surface is performed at least in part by reducing the proportion of non-silicon metal or metalloid atoms or both of the tentative contact surface. The method is performed by performing any one or any combination of these steps in any order.
[0093] Another aspect of the present disclosure is a customized biopharmaceutical product contact surface comprising the following statistical ratios of silicon, oxygen, carbon and hydrogen atoms, where the percentage of atoms other than hydrogen is determined by XPS and the percentage of hydrogen is determined by hydrogen forward scattering (HFS) analysis or Rutherford backscattering (RBS), Si=1:O=x:C=y:H=z, where x is from about 1.5 to about 2.9, y is from about 0 to about 1, and z is in the range of from about 0 to about 4.
[0094] Optionally, the customized biopharmaceutical product contact surface has a water contact angle of less than 90°. Optionally, the biopharmaceutical product contact surface has less than 1% H-bond donor groups as determined by X-ray photoelectron spectroscopy (XPS) and hydrogen forward scattering (HFS) analysis. Optionally, the biopharmaceutical product contact surface has less than 1% H-bond donor groups as determined by X-ray photoelectron spectroscopy (XPS) and Rutherford backscattering (RBS) analysis. Optionally, the biopharmaceutical product contact surface has at least 1% H-bond acceptor groups as determined by XPS and HFS analysis. Optionally, the biopharmaceutical product contact surface has at least 1% H-bond acceptor groups as determined by XPS and RBS analysis. Optionally, the customized biopharmaceutical product contact surface has less than 1% anionic and cationic groups as determined by XPS analysis. Optionally, the customized biopharmaceutical product contact surface is essentially free of metal or metalloid atoms other than silicon, as determined by XPS analysis.
[0095] Optionally, in any embodiment, the customized interface can be applied to at least one of the following types of containers to improve its compatibility with a particular biopharmaceutical product: 384-well plates, 96-well plates, bioreactors, blood collection tubes, bottles, bulk storage containers, cannulas, capture columns, cartridges, catheters, cell bank vials, cell separation devices, cell vials, centrifugal pumps, centrifuge tubes, chromatography columns, chromatography vials, clarifiers, sealed containers, container stopper systems, cryopreservation containers, culture bottles, shipping containers, diafiltration devices, dispensing units, ELISA plates, elution bags, evacuated blood collection tubes, fill / finish devices, filtration devices, freeze dryers, collection containers, shakers, in-process analytical equipment, intermediate columns, intravenous (IV) bags, media bags, media bottles, media containers, membrane chromatography columns, microplates, microtiter plates, microwell plates, mixing bottles, The bioreactors include, but are not limited to, a pack, a monitoring device, a multi-purpose bioreactor, a package filling device, a pump, a Petri dish, a pipette tip, a plate, a plunger, a polished column, a pre-filled syringe, a pre-filled syringe with a luer lock fitting, a primary packaging, a production bioreactor, a production fermenter, a roller bottle, a sampling tube, a sampling container, a seed fermenter, a separator, a shake flask, a single-use bioreactor, a slide, a spinner flask, a fixed needle pre-filled syringe, a storage bag, a sterilizer, a stock culture vial, a storage container, a syringe (pre-filled), a tank, an end reactor, a transport bag, an ultrafiltration / diafiltration device, an ultrafiltration device, an upstream bioreactor, a valve, a vial, a virus filtration device, a virus inactivation container, and a wave bioreactor. Optionally, in any embodiment, the modified interface can be applied to multiple (two, three, four, etc.) types of containers listed in the preceding list. Optionally, in any embodiment, the customized contact surface can be designated for use on the contact surfaces of at least two containers or devices that come into contact with the biopharmaceutical product during manufacturing, packaging, or distribution.
[0096] Surface features that prevent nonspecific protein adsorption In other embodiments of the present disclosure, multiple, preferably two or more, more preferably three or more, contacting surfaces are customized for a given biopharmaceutical product to prevent or reduce nonspecific protein adsorption, for example, by customizing a silica-based coating applied by plasma enhanced chemical vapor deposition ("PECVD"): (1) hydrophilic / polar surfaces, (2) surfaces with a substantial proportion of hydrogen bond acceptors, (3) surfaces without a substantial proportion of hydrogen bond donors, and (4) uncharged surfaces.
[0097] The composition of the coating on the interface can be tailored by adjusting the mixture ratio of organosilicon gas to oxygen gas flow rate and the applied voltage or power of the PECVD process. A wide variety of coatings can be produced with different bulk and surface properties. For example, pure and highly concentrated silica (i.e., SiO2) can be deposited with excellent gas and leachable barrier properties and hydrophilic surface properties. This is achieved by a high oxygen to organosilicon gas gas ratio in the gas mixture and high applied power. All the carbon from the organosilicon gas is converted to CO, a by-product of the reaction of the organosilicon gas with oxygen. x As a gas, it is removed from the process by a vacuum system.
[0098] Hydrophilic / polar surface In other embodiments, the silica-based coating can be optimized to provide a suitable water contact angle for contacting the biopharmaceutical product, for example, a contact angle of 30-60 degrees that is moderately hydrophilic.
[0099] Alternatively, the coating can be made more hydrophilic by maintaining a high oxygen to organosilicon ratio during PECVD but reducing the power. Water is a by-product of the reaction of organosilicon compounds with oxygen. At high power, water vapor is removed from the vacuum system. At low power, water vapor can become incorporated into the coating as silanol (i.e., Si-OH) groups. The silanol groups are polar and improve the surface hydrophilicity. In extreme cases, a water contact angle close to zero can be provided.
[0100] In another aspect, a more hydrophobic surface can be produced by reducing the oxygen to organosilicon flow ratio at moderate to low power. This incorporates non-polar aliphatic or other carbon and hydrogen containing groups into the surface, thus reducing hydrophilicity or increasing hydrophobicity. The resulting coating is more appropriately characterized as an organosilica or organosiloxane, since it contains silicon and oxygen atoms along with a substantial proportion of carbon atoms throughout its molecular structure. Alternatively, water contact angles of 80-100 degrees can be achieved in organosiloxane coatings. Further hydrophobicity can be incorporated by reducing polar groups and increasing surface roughness. This can be achieved by removing oxygen from the gas mixture as well as further selecting siloxane monomers with a higher carbon to oxygen ratio. Tetramethylsilane (SiC4H 12 ) and trimethylsilane (SiC3H 10 Silane monomers that do not have oxygen in their structure, such as silane monomers ...
[0101] Hydrogen Bond Acceptors and Donors In another aspect, these silica-based coatings can be optimized to provide coatings that have fewer hydrogen bond donors and more hydrogen bond acceptors.
[0102] Hydrogen bond donor groups contain a highly electronegative atom (e.g., O, N, Cl, F) covalently bonded to a hydrogen atom. Hydrogen bond acceptor groups contain a highly electronegative atom with only one pair of electrons. Hydrogen bonds are formed between hydrogen bond donor and acceptor groups. Hydrogen bonds are weaker than covalent and ionic bonds, but stronger than van der Waals bonds. Examples of hydrogen bond acceptors and donors in organic compounds are generally shown in Figure 1.
[0103] [Table 1]
[0104] A type of bond that is particularly useful in interfaces for many biopharmaceutical products is a hydrogen bond acceptor, rather than a hydrogen bond donor.
[0105] Uncharged Surface Some biopharmaceutical products have charged surfaces and such products tend to be modified by and adsorb onto charged contact surfaces, therefore in those situations it is generally preferable to customize the contact surface. EXAMPLES
[0106] All examples are based on silica-based coatings deposited by plasma enhanced chemical vapor deposition (PECVD). The precursor utilized during PECVD for all examples is hexamethyldisiloxane (HMDSO) mixed with oxygen gas. Alternative precursors in the siloxane chemical family can be used as well. The coatings can be deposited on any container or device useful in the discovery, development, manufacture, packaging and distribution of biopharmaceutical products. In all cases, the silica-based coating is in direct contact with the biopharmaceutical product.
[0107] Examples 1-3 provide preferred silica-based coatings that have utility for minimizing adsorption, denaturation, and aggregation of biological (i.e., protein) agents compared to conventional borosilicate glass or conventional plastics, and Example 4 provides a more preferred silica-based coating.
[0108] Achieving advantageous surface characteristics of silica-based coatings by PECVD that reduce or prevent protein adsorption, denaturation and aggregation is accomplished by adjusting the energy density of the plasma. The energy density of the plasma can be defined by the composite parameter W / FM in units of Joules per kilogram or J / kg. W corresponds to the applied power in watts, F is the flow rate in standard cubic centimeters per minute or sccm, and M is the molecular weight of the plasma polymerized component of the gas mixture. The following formula is used to calculate the W / FM of a mixture of HMDSO and oxygen gas in units of J / kg:
number
[0109] [Table 2]
[0110] The chemical reactions corresponding to the different coatings summarized in Table 1 are as follows: 1)SiO2C6H 18 +21 / 2 O2 → SiO2 +9 H2O +6 CO2; Example 1 2) SiO2C6H 18 +A O2 → B SiO x H z + CHO+DCO; Example 3 3)SiO2C6H 18 +A O2 → B SiO x C y H z + CH2O + DCO2; Examples 2 and 4
[0111] [Table 3]
[0112] Example 1 Described below are preferred contact surfaces with chemical characteristics that reduce interactions that lead to denaturation and aggregation of biopharmaceutical products: The silica-based coating is pure silicon dioxide (i.e., SiO2) with the following chemical functional group characteristics (Table 4): Net charge neutral (no anionic or cationic groups detected by XPS, less than 1%) ·Hydrophilic (water contact angle 30~80 degrees) Hydrogen bond donor groups (detected by XPS, less than 1%) No hydrogen bond acceptor groups (detected by XPS, less than 1%) Free of all aliphatic groups (detected by XPS, less than 1%), free of alkaline, alkaline, transition, metalloids (except Si) and post-transition metals
[0113] These characteristics are favorable for reducing the adsorption of more hydrophobic and charged proteins and peptides in biopharmaceutical products, as determined by radiolabeled protein adsorption studies. Adsorption is below 30 ng / cm 2 It is expected to be less than
[0114] Example 2 Below, we describe preferred contact surfaces with chemical characteristics that reduce interactions that lead to adsorption, denaturation, and aggregation of biopharmaceutical products. The silica-based coating is oreganosiloxane (i.e., SiO ) with the following chemical functional group characteristics (Table 4): x C y H z ). Net charge neutral (no anionic or cationic groups detected by XPS, less than 1%) ·Hydrophilic (water contact angle 50~90 degrees) Hydrogen bond donor groups (detected by XPS, 1-10%) No hydrogen bond acceptor groups (detected by XPS, less than 1%) No alkali, alkaline, transition, metalloid (except Si) or post-transition metals
[0115] These characteristics are favorable for reducing the adsorption of more hydrophilic and charged proteins and peptides in biopharmaceutical products, as determined by radiolabeled protein adsorption studies. Adsorption is below 30 ng / cm 2 It is expected to be less than
[0116] Example 3 Below, preferred contact surfaces are described that have chemical characteristics that reduce interactions that lead to denaturation and aggregation of biopharmaceutical products. The silica-based coating is a silicone oxide (i.e., SiO) coating with the following chemical functional group characteristics (Table 4): x H y ). Net charge neutral (no anionic or cationic groups detected by XPS, less than 1%) ·Hydrophilic (water contact angle <50 degrees) Hydrogen bond donor groups (Si-OH, detected by XPS, 1-50%) No hydrogen bond acceptor groups (detected by XPS, less than 1%) No alkali, alkaline, transition, metalloid (except Si) or post-transition metals
[0117] These characteristics are favorable for reducing the adsorption of more hydrophilic and charged proteins and peptides in biopharmaceutical products, as determined by radiolabeled protein adsorption studies. Adsorption is below 30 ng / cm 2 It is expected to be less than
[0118] Example 4 Below, we describe another preferred interface having chemical characteristics that reduce interactions that lead to denaturation and aggregation of biopharmaceutical products. The silica-based coating is a silicone oxide (i.e., SiO ) coating having the following chemical functional group characteristics (Table 4): x C y H z ). Net charge neutral (no anionic or cationic groups detected by XPS, less than 1%) ·Hydrophilic (water contact angle <50 degrees) No hydrogen bond donor groups (Si-OH, detected by XPS, less than 1%) Hydrogen bond acceptor groups (detected by XPS, 1-50%) No alkali, alkaline, transition, metalloid (except Si) or post-transition metals
[0119] These characteristics are favorable for reducing the adsorption of more hydrophilic and charged proteins and peptides in biopharmaceutical products, as determined by radiolabeled protein adsorption studies. Adsorption is below 30 ng / cm 2 It is expected to be less than
[0120] [Table 4]
[0121] Example 5 Protein adsorption on surfaces of containers for parenteral administration of biopharmaceutical products, especially proteins and antibodies, has been implicated as a precursor to protein aggregation. Aggregate formation of these products during preparation and subsequent complement activation can trigger adverse drug interactions (ADRs) in subjects to whom the biopharmaceutical products are administered. Proteins are denatured from the formulation by surface adsorption and subsequently shed as aggregates. Systems used in the manufacture and packaging of biopharmaceutical products, such as antibodies and recombinant proteins, should ideally include contact surfaces that minimize protein adsorption and reduce the risk of protein aggregate formation and ultimately ADRs.
[0122] IgG protein adsorption and retention on containers (e.g., tubes) whose surfaces are characterized by the contact surfaces of the present disclosure were compared to that of uncoated polymer, cyclic olefin polymer (COP) containers. The coating on the polymer tubes consisted of the unique silica (2 layers) and organosilica (3 layers) coatings of the present disclosure. The various reactants for the following studies described were: sodium azide (Sigma-Aldrich, MO), sodium iodide (NaI) (Sigma-Aldrich, MO), sodium phosphate monobasic (Fisher Scientific, NJ), sodium hydroxide (Fisher Scientific, NJ), sodium chloride crystals (NaCl) (EMD Millipore, MA) and citric acid hydrate (JT Baker, NJ).
[0123] IgG radiolabeling, purification and collection Bovine IgG (Sigma-Aldrich, MO) was radiolabeled using the iodine monochloride (ICl) method as modified in Horbett TAJBiomed. Mater. Res. (1981) 15(5):673-695. Briefly, 1 mCi of iodine-125 radionuclide (Perkin-Elmer, MA) was added to 0.5 ml 2× boric acid solution (Fisher Scientific, NJ) to which 0.5 ml of ICl / NaCl mixture in a 2:1 ratio was added. Then, 0.5 ml of 10 mg / ml bovine IgG in citrate phosphate buffer saline containing sodium azide (cPBSz) was added, and the iodination reaction was carried out on ice for 20 min, and then passed through a size-exclusion chromatography column. 40 fractions were collected to capture the labeled protein and free iodine peaks to assess iodination efficiency. Fractions from the protein peak were combined and pooled and passed through a second chromatography column, and fraction collection and peak identification were repeated. The purified, labeled protein fractions were combined and pooled, placed in a lead container, and frozen in a -80°C freezer until further use.
[0124] Protein adsorption study Prior to protein adsorption studies, treated tubes (n=5 per group of 2-layer coated tubes, 3-layer coated tubes, and uncoated COP tubes) were immersed in 1 ml of cPBS solution containing 10 mM NaI (cPBSzI) for 1 hour. For adsorption, the labeled IgG was thawed and then added to a 0.1 mg / mL solution of bovine IgG in cPBSzI to create radiolabeled bovine IgG or "hot" protein. The cPBSzI buffer was aspirated with a transfer pipette, after which 1 mL of "hot" protein was added to each tube and allowed to adsorb for 2 hours, followed by rinsing three times with cPBSzI. The radioactivity of each rinsed tube was then measured for 1 minute along with a protein standard using a Perkin Elmer Wizard2 gamma counter.
[0125] Protein Retention Study To assess protein retention in the tubes, i.e. how tightly the protein is retained on the surface of the tubes, we first adsorbed "radioactive" IgG proteins in tubes (n=10 / group) for 2 hours as described above. Then, 1 ml of 1% SDS solution was added to each of the tubes and left overnight to extract the IgG proteins. The SDS solution was aspirated using a transfer pipette, the tubes were again rinsed three times with cPBSzI and their radioactivity was measured for 1 minute together with protein standards using a Perkin Elmer Wizard2 gamma counter. Untreated tubes were used as controls. Adsorption and retention data are reported in ng / cm 2 reported.
[0126] As shown in Figure 1a, tubes containing two- and three-layer coatings show 1 / 4 to 1 / 5 IgG protein adsorption compared to uncoated COP tubes. As shown in Figure 1b, SDS extraction is able to remove the adsorbed IgG protein from all tubes. However, a larger amount of adsorbed IgG protein is retained on the surface of the uncoated COP tube compared to that retained in the tubes containing two- or three-layer coatings. Finally, a larger amount of adsorbed protein was removed from the uncoated COP tube after rinsing compared to the coated vessels.
[0127] result These results demonstrate that the disclosed system with a contact surface comprising a two-layer or three-layer coating provides a conformal surface that minimizes protein adsorption and retention on the surface of the coated container.
Claims
1. 1. A system comprising at least two containers or connectors for use in the manufacture, packaging or distribution of a biopharmaceutical product, each of said containers comprising a wall defining an internal cavity, said containers being optionally open or openable at one end or side, said wall of each of said containers having an interior surface facing said cavity, said interior surface being characterized by a common surface present on said wall in substantially all areas where said interior surface contacts said biopharmaceutical product, said common surface comprising a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bond coating or layer is made of SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bond coating or layer has an exterior surface facing the wall of the container and an interior surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer having an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and said pH protective coating or layer has an outer surface facing said inner surface of said barrier coating or layer and an inner surface facing said cavity.
2. The container is selected from the group consisting of 384-well plates, 96-well plates, bioreactors, blood collection tubes, bottles, bulk storage containers, cannulas, capture columns, cartridges, catheters, cell bank vials, cell separators, cell vials, centrifugal pumps, centrifuge tubes, chromatography columns, chromatography vials, clarifiers, sealed containers, container stopper systems, cryopreservation containers, culture bottles, shipping containers, diafiltration equipment, dispensing units, ELISA plates, elution bags, evacuated blood collection tubes, fill / finish equipment, filtration equipment, freeze dryers, collection containers, shakers, in-process analytical equipment, intermediate columns, intravenous (IV) bags, media bags, media bottles, media containers, membrane chromatography columns, microplates, microtiter plates, microwell plates, mixing bags, monitoring equipment, multipurpose bags, 2. The system of claim 1, wherein the bioreactor is selected from the group consisting of one or more of: bioreactor, package filling device, pump, petri dish, pipette tip, plate, plunger, polished column, prefilled syringe, prefilled syringe with luer lock fitting, primary packaging, production bioreactor, production fermenter, roller bottle, sampling tube, sampling container, seed fermenter, separator, shake flask, single use bioreactor, slide, spinner flask, fixed needle prefilled syringe, storage bag, sterilizer, stock culture vial, storage container, syringe (prefilled), tank, end reactor, transport bag, ultrafiltration / diafiltration device, ultrafiltration device, upstream bioreactor, valve, vial, virus filtration device, virus inactivation container, and wave bioreactor.
3. 3. The system of claim 2, wherein at least one of the containers is selected from the group consisting of a bioreactor, a pump, a cell bank vial, a harvest vessel, a stock culture vial, a fermenter, a shake flask, a shaker, a column, a separator, a bag, a beaker, a tank, a cylinder, a bulk storage unit or vessel, a single-use bag, a roller bottle, a storage tube, and a sampling vessel.
4. 3. The system of claim 2, wherein at least one of the containers is selected from the group consisting of a syringe, a dispensing unit, a vial, and an intravenous (IV) bag.
5. The at least two containers include (a) a first container useful for holding a bulk quantity of the biopharmaceutical product, and (b) a second container useful for administering a composition comprising at least a portion of the biopharmaceutical product to a subject in need. A system according to any one of claims 1 to 4.
6. 6. The system of claim 5, further comprising one or more connectors connecting one or more of the containers to one or more other containers or connectors, wherein at least one of the containers in one or more series has a wall, the inner surface of the wall being characterized by a surface present on the wall in substantially all areas that contact the biopharmaceutical product being manufactured, the surface being common to the innermost surfaces of the first container and the second container.
7. 7. The system of claim 6, wherein one of the vessels in the one or more series of vessels is independently selected from the group consisting of a bioreactor, a fermenter, a pump, a roller bottle, a flask, a shaker, a separator, a bag, a beaker, a sampling vessel, a cylinder, a pipette tip, a slide, and a vial.
8. 8. The system of claim 6 or 7, wherein at least one of the containers in the one or more series of containers is connected to another of the containers in the one or more series of containers via one or more connectors, at least one of the connectors comprising a wall defining an internal cavity, the wall having an inner surface characterized by a surface present on the wall in substantially all areas that contact the biopharmaceutical product being manufactured, the surface being common to the innermost surfaces of the first container and the second container.
9. 9. The system of claim 8, wherein each connector is independently selected from the group consisting of tubing, tubing, valves, and pipes.
10. 6. The system of claim 5, further comprising one or more series of containers useful in the production of the bulk quantity of the biopharmaceutical product, wherein at least one of the containers in the one or more series has a wall, the interior surface of the wall being characterized by a surface present on the wall in substantially all areas that contact the biopharmaceutical product being manufactured, the surface being not common to surfaces of the first container and the second container, and the surface present on the wall in substantially all areas that contact the biopharmaceutical product being manufactured is common to the surface on the wall of at least one other of the containers in the one or more series.
11. the common surface comprises a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bond coating or layer is made of SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bond coating or layer has an exterior surface facing the wall of the container and an interior surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer having an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y 11. The system of claim 10, comprising: x is from about 0.5 to about 2.4; y is from about 0.6 to about 3; and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and an inner surface facing the cavity.
12. 1. A system comprising at least two containers or connectors useful for evaluating one or more characteristics of a biopharmaceutical product, namely one or more of quality, purity and integrity, each of said containers comprising a wall defining an internal cavity, said containers optionally being open or openable at one end or at one side, said wall of each of said containers having an interior surface facing said cavity, said interior surface being characterized by a common surface present on said wall in substantially all areas where said interior surface contacts said biopharmaceutical product, said common surface comprising a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bond coating or layer is made of SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bond coating or layer has an exterior surface facing the wall of the container and an interior surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer having an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and said pH protective coating or layer has an outer surface facing said inner surface of said barrier coating or layer and an inner surface facing said cavity.
13. 13. The system of claim 12, wherein the common surface is not the same as the common surface of the first container and the second container of claim 5, the common surface of the one or more containers of claim 9, or any of them.
14. The system of claim 12, wherein the common surface is identical to one or both of the common surface of the first container and the second container of claim 5 and the common surface of the one or more containers of claim 9.
15. 13. The system of claim 11 or 12, wherein each container is selected from the group consisting of a microplate, a microtiter plate, a microwell plate, and a Petri dish.
16. 16. The system of any one of claims 1 to 15, wherein the biopharmaceutical product is selected from the group consisting of one or more of: an antibody, a bulk biopharmaceutical preparation, a cell culture preparation, a cell suspension, a culture medium, a biopharmaceutical product, a biopharmaceutical substance, a biopharmaceutical preparation, an expression vector / host preparation, a harvested cell preparation, a host cell composition, a host cell contaminant, a mobile phase, a monoclonal antibody preparation, a product stream, a seed train composition, a stationary phase, a peptide or protein formulation, and a nucleic acid formulation.
17. 1. A method of manufacturing a system comprising at least two containers or connectors useful in the manufacture, packaging or distribution of a biopharmaceutical product, each of said containers or connectors comprising a wall defining an internal cavity, said containers or connectors optionally being open or openable at one end or side, said wall of each of said containers or connectors having an interior surface facing said cavity, comprising: Providing a biopharmaceutical product; - providing a temporary contact surface; - determining whether the biopharmaceutical product is compatible with the provisional contact surface; - modifying the provisional interface to improve its compatibility with the biopharmaceutical product, thereby producing a customized interface; using the customized contact surface to manufacture the system such that the interior surface of the container / connector is characterized by a customized common surface present on the interior surface in substantially all areas where the interior surface contacts the biopharmaceutical product, the customized common surface including a bonding coating or layer, a barrier coating or layer, and optionally a pH protective coating or layer; o The bond coating or layer is made of SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the bond coating or layer has an exterior surface facing the wall of the container and an interior surface facing the cavity; o The barrier coating or layer is SiO x wherein x is 1.5 to 2.9, the barrier coating or layer is 2 to 1000 nm thick, the barrier coating or layer having an outer surface facing the inner surface of the bonding coating or layer and an inner surface facing the cavity; o The pH protective coating or layer is SiO x C y or SiN x C y wherein x is from about 0.5 to about 2.4 and y is from about 0.6 to about 3, and the pH protective coating or layer has an outer surface facing the inner surface of the barrier coating or layer and an inner surface facing the cavity; A method comprising:
18. 20. The method of claim 17, wherein the biopharmaceutical product is selected from the group consisting of one or more of an antibody, a bulk biopharmaceutical preparation, a cell culture preparation, a cell suspension, a culture medium, a biopharmaceutical product, a biopharmaceutical substance, a biopharmaceutical preparation, an expression vector / host preparation, a harvested cell preparation, a host cell composition, a host cell contaminant, a mobile phase, a monoclonal antibody preparation, a product stream, a seed train composition, a stationary phase, a peptide or protein formulation, and a nucleic acid formulation.
19. 19. The method of claim 17 or 18, wherein the tentative contact surface has a water contact angle of less than 90°.
20. 20. The method of any one of claims 17 to 19, wherein the tentative contact surface has less than 1% H-bond donor groups as determined by X-ray photoelectron spectroscopy (XPS) and optionally hydrogen forward scattering (HFS) analysis or Rutherford backscattering (RBS) analysis.
21. 21. The method of any one of claims 17 to 20, wherein the tentative contact surface has at least less than 1% H-bond acceptor groups as determined by XPS and optionally HFS or RBS analysis.
22. 22. The method of any one of claims 17 to 21, wherein the tentative contact surface has less than 1% anionic and cationic groups as determined by XPS.
23. A method according to any one of claims 17 to 22, wherein the tentative contact surface is substantially free of metal or metalloid atoms other than silicon as determined by XPS.
24. The method of any one of claims 17 to 23, wherein the preliminary contact surface is a plasma enhanced chemical vapor deposition (PECVD) coating.
25. 25. The method of any one of claims 17 to 24, wherein the tentative contact surface has the following statistical ratios of silicon, oxygen, carbon and hydrogen atoms as determined by XPS and optionally HFS or RBS: Si=1:O=x:C=y:H=z, where x is from about 1.5 to about 2.9, y is from about 0 to about 1, and z is in the range of from about 0 to about 4.
26. 25. The method of any one of claims 17 to 24, wherein the tentative contact surface has the following statistical ratios of silicon, oxygen, carbon and hydrogen atoms as determined by XPS and optionally HFS or RBS: Si=1:O=x:C=y:H=z, where x is from 0.5 to 2.4, y is from 0.6 to 3 and z is from 2 to 9.
27. 25. The method of any one of claims 17 to 24, wherein the tentative contact surface has the following statistical ratios of silicon, oxygen, carbon and hydrogen atoms as determined by XPS and optionally HFS or RBS: Si=1:O=x:C=y:H=z, where x is between 1.5 and 2.9, y is about 0 and z is about 0.
28. The container may be a 384-well plate, a 96-well plate, a bioreactor, a blood collection tube, a bottle, a bulk storage container, a cannula, a capture column, a cartridge, a catheter, a cell bank vial, a cell separator, a cell vial, a centrifugal pump, a centrifuge tube, a chromatography column, a chromatography vial, a clarifier, a sealed container, a container stopper system, a cryopreservation container, a culture bottle, a shipping container, a diafiltration device, a dispensing unit, an ELISA plate, an elution bag, a vacuum blood collection tube, a fill / finish device, a filtration device, a freeze dryer, a collection container, a shaker, an in-process analytical device, an intermediate column, an intravenous (IV) bag, a media bag, a media bottle, a media container, a membrane chromatography column, a microplate, a microtiter plate, a microwell plate, a mixing bag, a monitoring device, a multipurpose bioreactor, a 28. The method of any one of claims 17 to 27, wherein the bioreactor is selected from the group consisting of one or more of: a bioreactor, a package filling device, a pump, a Petri dish, a pipette tip, a plate, a plunger, a polished column, a prefilled syringe, a prefilled syringe with luer lock fitting, a primary packaging, a production bioreactor, a production fermenter, a roller bottle, a sampling tube, a sampling container, a seed fermenter, a separator, a shake flask, a single use bioreactor, a slide, a spinner flask, a fixed needle prefilled syringe, a storage bag, a sterilizer, a stock culture vial, a storage container, a syringe (prefilled), a tank, an end reactor, a transport bag, an ultrafiltration / diafiltration device, an ultrafiltration device, an upstream bioreactor, a valve, a vial, a virus filtration device, a virus inactivation container and a wave bioreactor.
29. The method of modifying said temporary contact surface of a container to improve its compatibility with a particular biopharmaceutical product to produce a customized contact surface comprises the steps of: - reducing the water contact angle of the provisional contact surface by about 10% to 90% of the original water contact angle; reducing the proportion of H-bond donor groups at said tentative interface by about 10% to 90% as determined by XPS and, optionally, HFS or RBS analysis; Increasing the percentage of H-bond acceptor groups at said tentative interface by about 10% to 90% as determined by XPS and, optionally, HFS or RBS analysis; reducing the percentage of anionic groups, cationic groups, or both, at the tentative interface by about 10% to 90% as determined by XPS analysis; reducing the percentage of metal or metalloid atoms other than silicon at said tentative contact surface by about 10% to 90% as determined by XPS analysis; The method according to any one of claims 17 to 28, comprising at least one of the following:
